CareDx (NASDAQ:CDNA) Director Hannah Valantine Sells 12,103 Shares of Stock

CareDx, Inc. (NASDAQ:CDNA) Director Hannah Valantine sold 12,103 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $23.11, for a total transaction of $279,700.33. Following the transaction, the director directly owned 36,686 shares of the company’s stock, valued at approximately $847,813.46. This represents a 24.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

CareDx Trading Down 3.4%

Shares of NASDAQ:CDNA opened at $23.25 on Wednesday. The company has a 50 day moving average of $21.03 and a 200 day moving average of $19.70. The stock has a market cap of $1.20 billion, a P/E ratio of -145.31 and a beta of 2.49. CareDx, Inc. has a 12 month low of $10.96 and a 12 month high of $24.85.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.11 by $0.23. The company had revenue of $117.70 million during the quarter, compared to analysts’ expectations of $102.03 million. CareDx had a negative net margin of 2.01% and a negative return on equity of 2.65%. CareDx’s revenue for the quarter was up 39.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.09 earnings per share. On average, equities analysts forecast that CareDx, Inc. will post 0.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on CDNA shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of CareDx in a research note on Wednesday, May 27th. Wells Fargo & Company lifted their target price on shares of CareDx from $18.00 to $21.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. BTIG Research lifted their target price on shares of CareDx from $26.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Finally, Wall Street Zen upgraded shares of CareDx from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 3rd. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $25.00.

Institutional Investors Weigh In On CareDx

Several hedge funds have recently bought and sold shares of CDNA. Deerfield Management Company L.P. bought a new stake in shares of CareDx in the 3rd quarter worth approximately $31,857,000. Braidwell LP bought a new stake in shares of CareDx in the 3rd quarter worth approximately $31,738,000. Boston Partners lifted its holdings in shares of CareDx by 2,776.5% in the 4th quarter. Boston Partners now owns 901,929 shares of the company’s stock worth $16,994,000 after acquiring an additional 870,574 shares during the last quarter. Bamco Inc. NY lifted its holdings in shares of CareDx by 29.5% in the 3rd quarter. Bamco Inc. NY now owns 3,155,180 shares of the company’s stock worth $45,876,000 after acquiring an additional 719,523 shares during the last quarter. Finally, Amova Asset Management Americas Inc. lifted its holdings in shares of CareDx by 40.8% in the 3rd quarter. Amova Asset Management Americas Inc. now owns 1,740,064 shares of the company’s stock worth $25,283,000 after acquiring an additional 504,473 shares during the last quarter.

About CareDx

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.